SureTrader Stock Hero Advertisement
Home > Boards > US OTC > Medical - Drugs >

Ocata Therapeutics Inc. (OCAT)

OCAT RSS Feed
Add OCAT Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator elysse1kittycat, sports guy, Auger08, LODE MAKING ME RICH, homeslice10, lasers
Search This Board:
Last Post: 4/26/2015 5:53:15 PM - Followers: 637 - Board type: Free - Posts Today: 17


 Ocata Therapeutics (OCAT)

formerly Advanced Cell Technology (ACTC):
Advanced Cell Technology Changes Name to Ocata Therapeutics

https://www.ocata.com/
 

Ocata Therapeutics Headquarters
33 Locke Drive
Marlborough, MA 01752
Tel: (508) 756-1212
Fax: (508) 229-2333
info@ocata.com 
 

Company Overview

Ocata Therapeutics, Inc. (“Ocata”; OTCBB: OCAT), formerly named Advanced Cell Technology, is a clinical stage biotechnology company focused on the development and commercialization of new therapies in the field of regenerative medicine. Regenerative medicine is defined as the process of replacing or regenerating human cells, tissues or organs to restore or establish normal function and has been called the “next evolution of medical treatments” and “the vanguard of 21st century healthcare” by the U.S. Department of Health and Human Services.

The company’s principal R&D and commercial efforts relate to its Regenerative Ophthalmology™ programs and involve development of therapies for the treatment of eye diseases and disorders. Beyond the eye, our other research areas include projects focusing on developing many different cell therapies that may be used to treat a range of diseases across several therapeutic categories. Ocata’s principal laboratory, GMP facility and corporate offices are in Marlborough, Massachusetts. 
 

Regenerative Ophthalmology Platform

The mission behind our Regenerative Ophthalmology efforts is clear. It is our goal to bring innovative new therapies to the market to treat diseases of the eye that otherwise may cause significant loss of vision in patients. Our emerging cell therapies focus on structural repair and functional restoration and have the potential to make a significant difference in the lives of people with ocular disorders.

We are at the forefront of developing new therapies to address some of the most significant unmet medical needs in eye diseases. These include potential treatments for diseases affecting the retina, such as age-related macular degeneration – as well as other forms of macular degeneration, diabetic retinopathy and retinitis pigmentosa, as well as inflammatory diseases such as uveitis, and vision loss from photoreceptor and other neurosensory retinal damage due to glaucoma.

  • Our lead clinical program involves RPE Cell Therapy for treating macular degeneration. Critical to the development and the rate of progression of macular degeneration is the health status of the retinal pigment epithelium, or RPE, a single layer of cells whose presence and integrity in the retina are required for normal vision. The company is currently conducting clinical trials in the U.S. andU.K. for treating Stargardt’s macular degeneration with the RPE Cell Therapy, and in the U.S. for treating patients with dry age-related macular degeneration.
    We are developing a Photoreceptor Progenitor Cell Therapy which we intend to be used for treating a wide variety of retinal degenerations in diseases where photoreceptors malfunction and/or die.
    Our Ganglion Progenitor Cell Therapy is a preclinical candidate program. In animal models of glaucoma, the injection of these cells protects against damage of existing nerve cells as well as forms new ganglion nerve cells.
    The company is also developing therapeutic platforms using Corneal Endothelial Cells for use in treating corneal blindness.

See our Pipeline of Ophthalmology Therapies »


Other Regenerative Medicine Programs

In addition to our regenerative ophthalmology programs we have invested in other programs where we feel that we can leverage our expertise in cellular and developmental biology to generate allogeneic therapies that have the potential to improve health care in other prevalent degenerative diseases and diseases of aging. At the core of our pipeline planning are approaches intended to address large unmet medical needs with allogeneic stem cell-derived therapeutics.

Our Mesenchymal Stem Cells

Our Mesenchymal Stem Cells (MSCs) represent an “off-the-shelf” cellular therapy ready for treatment of autoimmune and inflammatory diseases in both acute and chronic settings. MSCs regulate immune and inflammatory responses, providing therapeutic potential for treating diseases characterized by the presence of an inflammatory component, which makes them an attractive tool for the cellular treatment of autoimmunity and inflammation. We believe we have succeeded at creating a differentiated MSC product by producing the cells in culture from a pluripotent stem cell source.

Neuroprotective Biologics

We have discovered Neuroprotective Biologics that are secreted by certain of our neurosensory retina progenitor cell populations. We anticipate that the neuroprotective agent(s) that we may ultimately develop as drug candidates may be useful not only in retinal diseases and dystrophies, but may have broader applications in central nervous system and peripheral nervous system diseases and disorders, including diseases causing cognitive function impairment, movement disorders such as Parkinson’s Disease, and ischemic events such as caused by stroke.

Blood Components Programs

Through our Blood Components Programs, we have been able to generate Red Blood Cells, Platelets, Dendritic cells and other cells relevant immune response or hemostasis.

 

Pipeline of Therapeutic Programs

Ocata’s world-class research and development programs embody our efforts to bring transformative new therapies to market for patients facing some of hardest-to-treat eye diseases and disorders.

Filings:

http://www.sec.gov/cgi-bin/browse-edgar?company=&match=&CIK=0001140098&filenum=&State=&Country=&SIC=&owner=exclude&Find=Find+Companies&action=getcompany
 

 

 


Press Releases

 

 

 

 



 


All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.

 

 

 

Rules of the board according to IHUB:
http://www.investorshub.com/boards/complex_terms.asp


 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
OCAT
Current Price
Volume:
Bid Ask Day's Range
Wiki
PostSubject
#76767  Sticky Note Ocata Therapeutics Receives Advanced Therapy Medicinal Product Designation lasers 11/24/14 12:12:44 PM
#74805  Sticky Note ACT Announces Positive Results from Two Clinical Trials LittleDutchDenny 10/14/14 09:50:43 PM
#83567   The hard reality is, that anyone studying the farviewhill 04/26/15 05:53:15 PM
#83566   Bought into ACTC last May 22, 2014. Humbug 04/26/15 05:32:03 PM
#83565   LOL quote , "If anyone takes the 98% Captain Kirk 04/26/15 04:26:18 PM
#83564   Once again you are absolutely right, Captain Kirk. elllk 04/26/15 03:26:01 PM
#83563   It's Down 98%, Why Are You Here? rumper 04/26/15 03:22:17 PM
#83562   OCAT: Some information out there. chuckanutman 04/26/15 02:02:52 PM
#83561   Why is this article quoting Arnold I Caplan Hank615 04/26/15 01:50:43 PM
#83560   OCAT Post from Scotty2: chuckanutman 04/26/15 01:46:35 PM
#83558   Who is down 98%? STEM? I thought it tsoprano-1 04/26/15 12:15:36 PM
#83555   For me this is an important week all elysse1kittycat 04/26/15 11:42:32 AM
#83554   LOL quote, "a company who's common shares have Captain Kirk 04/26/15 10:31:18 AM
#83553   LOL QUOTE: company has LITTLE chance to survive Trader Joey 04/26/15 10:00:41 AM
#83552   LOL Quote: a company who's common shares have Trader Joey 04/26/15 09:51:50 AM
#83549   I have a hard time understanding the concern Killtoy 04/25/15 10:00:05 PM
#83547   I've been trying to understand what the controversy rumper 04/25/15 07:00:14 PM
#83546  Restored Quote total BS LOL, " Dr. Lanza is Captain Kirk 04/25/15 06:18:12 PM
#83544   Hank615 Welcome to the MB. Dr. Lanza lasers 04/25/15 04:46:32 PM
#83543   HANK, looks like a new investor and poster. farviewhill 04/25/15 04:18:03 PM
#83542   Ah, retrospect investing! farviewhill 04/25/15 04:08:44 PM
#83541   Our doc is a genius ... runcaly 04/25/15 03:59:08 PM
#83540   Lanza rubbing elbows with the powerful on May 14 Hank615 04/25/15 12:35:23 PM
#83539   Robert Lanza talks on Monday 4-27-2015 at 9:00 Hank615 04/25/15 12:25:11 PM
#83538   Fidelity and Vanguard have interest in OCAT. Why chuckanutman 04/25/15 10:46:24 AM
#83537   The buy on the rumor and sell on elysse1kittycat 04/25/15 09:19:14 AM
#83536   Wondering if this sells off after Lanza talk Gastrodamas 04/25/15 08:36:34 AM
#83535   500 shares more for me yesterday, runcaly 04/25/15 05:52:54 AM
#83534   A GREEN Friday close. Thats good news to Gastrodamas 04/24/15 08:54:19 PM
#83530   Imo most investors will agree with your post guy3 04/24/15 03:15:12 PM
#83529   LOL quote, "And this is where we find Captain Kirk 04/24/15 02:56:19 PM
#83527   LOL, Using Charts to Forecast The Future rumper 04/24/15 02:33:00 PM
#83526   Bits and clips from Stemdynasty: chuckanutman 04/24/15 01:38:30 PM
#83525   LOL, it's not even a 52 week or Captain Kirk 04/24/15 12:38:20 PM
#83524   Informational post from Stemdynasty: chuckanutman 04/24/15 12:21:45 PM
#83523   OCAT was downgraded to a hold by Maxim, AyeEye 04/24/15 12:07:05 PM
#83522   IMO the $8 by itself means steady accumulation lasers 04/24/15 10:18:27 AM
#83521   Ouch OT StemCells, Inc. Announces Pricing of Public Offering to runcaly 04/24/15 10:17:36 AM
#83520   Significance of $8 on May 15? fatty buggah 04/24/15 10:14:04 AM
#83519   With the Options buyers betting on $OCAT at lasers 04/24/15 10:11:04 AM
#83518   it seems the accumulation will continue ... fatty buggah 04/24/15 10:05:50 AM
#83517   With the $7.50 May $OCAT Call options going lasers 04/24/15 10:03:16 AM
#83516   $OCAT Covered Short interest for mi-Apr should be lasers 04/24/15 09:43:33 AM
#83515   Bulls seem to be winning that battle so Reetala 04/24/15 09:34:43 AM
#83514   $OCAT PPS is in uncharted waters of what lasers 04/24/15 09:32:05 AM
#83513   Lanza's presentation at StemConn 2015 on the 27th Reetala 04/24/15 09:28:19 AM
#83512   I shorted trying to gain some shares and fatty buggah 04/24/15 08:09:33 AM
#83511   I've posted a few times over the past farviewhill 04/23/15 08:42:29 PM
#83510   Shire as a JV candidate for $OCAT is lasers 04/23/15 07:52:10 PM
#83509   Info from Bogeyfree and Twenty2: chuckanutman 04/23/15 07:21:25 PM
#83508   AHs buying at $7.50, 300 shares so far. lasers 04/23/15 06:53:39 PM
#83507   $OCAT PPS $7.48 is the battle front. When lasers 04/23/15 02:33:35 PM
PostSubject